Early side effects and first results of radioligand therapy with 177Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre studyReport as inadecuate




Early side effects and first results of radioligand therapy with 177Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study - Download this document for free, or read online. Document in PDF available to download.

EJNMMI Research

, 5:36

First Online: 20 June 2015Received: 27 April 2015Accepted: 05 June 2015DOI: 10.1186-s13550-015-0114-2

Cite this article as: Ahmadzadehfar, H., Rahbar, K., Kürpig, S. et al. EJNMMI Res 2015 5: 36. doi:10.1186-s13550-015-0114-2

Abstract

BackgroundRadioligand therapy RLT with Lu-DKFZ-617 PSMA Lu-PSMA prostate-specific membrane antigen is a novel targeted therapy of metastatic prostate cancer. We analysed retrospectively the early side effects and the response rate in the first patients, who received a therapy with Lu-PSMA in our departments.

MethodsRLT was performed in ten hormone- and-or chemo-refractory patients with distant metastases and progressive disease mean age 73.5 years. Ga-PSMA HBED-CC PET-CT was performed in all patients prior to RLT. The median PSA level prior to the therapy was 298.5 ng-ml range 5–853 ng-ml. All patients received CBC, renal and liver function tests the day before and 2 days after application mean administered activity 5.6 GBq, range 4.1–6.1 GBq, followed by further tests every 2 weeks. All patients were contacted by telephone every week regarding side effects or any positive and negative changes.

ResultsEight weeks after the therapy, seven patients 70 % experienced a PSA decline, of whom six experienced more than 30 % and five more than 50 %. Three patients showed a progressive disease according to the PSA increase. No patient experienced any side effects immediately after injection of Lu-PSMA. Relevant hematotoxicity grade 3 or 4 occurred 7 weeks after the administration in just one patient. The same patient showed a leucopenia grade 2. Two patients showed a disturbance of only 1 hematologic cell line, whereas one patient showed a reduction of grades 1 and 2 in leucocytes and thrombocytes, respectively. Six patients did not show any hematotoxicity during the 8 weeks after therapy. There was no relevant nephrotoxicity grade 3 or 4.

ConclusionsOur initial results indicate that RLT with Lu-PSMA is safe and seems to have low early side-effect profile. A relevant PSA decline was detected in 70 % of patients.

KeywordsProstate cancer PSMA Radioligand therapy 177Lu Hojjat Ahmadzadehfar and Kambiz Rahbar contributed equally to this work.

Download fulltext PDF



Author: Hojjat Ahmadzadehfar - Kambiz Rahbar - Stefan Kürpig - Martin Bögemann - Michael Claesener - Elisabeth Eppard - Florian G

Source: https://link.springer.com/







Related documents